The simultaneous measurement of DNA content and myeloma-related antigens (B-B4 or CD38) by flow cytometry is proposed as a method for the detection of aneuploid plasma cells in peripheral blood stem cell (PBSC) harvests and in bone marrow after therapy. In 30 patients with initially detected aneuploid myeloma cells we evaluated the bone marrow after therapy and in eight of these patients 23 PBSC harvests were analyzed. In 13 of 23 PBSC harvests aneuploid myeloma cells were detectable (range: 0.02-0.63%). In the bone marrow of the 30 patients aneuploid plasma cells were detectable in all samples after chemotherapy (range: 0.12-35.70%) and after autologous PBSC transplantation in two of three patients (0.21% and 0.03%). Furthermore the relationship between diploid and aneuploid plasma cells can be evaluated. In the PBSC harvests the percentage of aneuploid plasma cells is significantly lower than that of diploid plasma cells (P = 0.006). In contrast, in bone marrow the aneuploid plasma cells are predominant in most patients even after therapy (24 of 30 patients; P = 0.0055). In the case of initially detected aneuploid myeloma cells, a contamination with malignant cells can be estimated with a simple flow cytometric method in PBSC harvests and in bone marrow after therapy.
The survival of patients with multiple myeloma (MM) after autologous bone marrow transplantation is superior compared to the results of conventional chemotherapy. 1 A further improvement of therapy results might be expected from the transplantation of autologous peripheral blood stem cells (PBSC). It has been assumed that these transplants may be contaminated with fewer malignant plasma cells than those from bone marrow. However, a small number of malignant plasma cells are also detectable in leu-kapheresis products after mobilization of PBSC with G-CSF. [2] [3] [4] It has been shown in other malignancies that the retransplantation of malignant cells even in a low quantity may contribute to relapse 5 and thus has influence on the clinical outcome of patients. 6 The quantification of residual malignant plasma cells is performed by detection of disease-or clone-specific characteristics. At first, the light chain restriction of myeloma cells can be measured by fluorescence microscopy 7 or by flow cytometry. 8 Secondly, the analysis of clone-specific complementarity determining region (CDR) III is the most sensitive tool for the detection of myeloma cells. [9] [10] [11] Another characteristic of myeloma cells is the abnormal expression of the CD56 antigen 12 and the abnormal DNA content (DNA aneuploidy), detectable with flow cytometry in 50-80% of the cases. [13] [14] [15] [16] Using aneuploidy as a marker we propose a new, simple and sensitive method for the detection of malignant cells in leukapheresis samples and in bone marrow after therapy.
Patients and methods

Patients
After informed consent 52 patients with multiple myeloma and indications for chemotherapy were investigated consecutively between August 1995 and January 1998. In 30 out of 52 (58%) patients aneuploid myeloma cells were detected. These patients were enrolled in this study. According to the staging of Salmon and Durie, 17 24 patients were in stage IIIA, three patients in stage IIIB and the other three patients in stage IIA with progression.
PBSC harvests (n = 23) of eight patients were investigated after mobilization therapy with high-dose cyclophosphamide (4 g/m 2 ) and G-CSF (5 g/kg/day). PBSC were collected using a COBE Spectra (Lakewood, CO, USA). No more than three aphereses were successively performed after mobilization therapy.
Bone marrow samples of 30 patients with initially detected aneuploidy were investigated after at least three cycles of chemotherapy (melphalan/prednisolone, highdose cyclophosphamide or vincristine, doxorubicin, dexamethasone) and from three patients after autologous PBSC transplantation.
Preparation of cells for flow cytometric analysis
The method of simultaneous immunophenotyping and DNA quantification by flow cytometry was used for the detection of small numbers of aneuploid myeloma cells. Bone marrow cells were separated by density gradient (Lymphoprep, 1.077 g/ml; Nycomed, Oslo, Norway), washed in phosphate-buffered saline (PBS; Seromed, Berlin, Germany) and counted. The cells from leukapheresis samples were washed in PBS and counted. For immunophenotyping the indirect method was preferred because of the much higher quantity of the bound FITC molecules per antigen compared to the direct immunophenotyping. For this, cells were incubated with monoclonal antibodies (anti-B-B4, clustered as anti-CD38, DPC Biermann, Bad Nauheim, Germany) for 30 min at 4°C. After washing with PBS the cells were incubated with goat anti mouse IgG F(ab) 2 fragment (Coulter Immunotech Diagnostics, Hamburg, Germany) for 10 min at room temperature. The cells were washed twice in PBS and then prepared for cell cycle analysis as described previously.
14 Briefly, after immunophenotyping cells were thoroughly resuspended and cold ethanol (−20°C) was added. The specimens were stored overnight at 4°C. After washing and resuspending in PBS the cells were incubated with RNAse (25 mg/ml, Sigma, Deisenhofen, Germany) and propidium iodide (PI, 1 mg/ml, Sigma) for at least 15 min at room temperature.
Flow cytometric analysis
Cell samples were measured on a FACScan flow cytometer (Becton Dickinson, San Jose, CA, USA) with the usual filter configuration. List mode data were acquired and analyzed with FACS Lysis II software (Becton Dickinson). The DNA content of at least 50 000 cells was recorded. For the documentation of sufficient numbers of plasma cells in the PBSC harvests and bone marrow after chemotherapy an additional live gate measurement was performed. This live gate was set in the dot plot of fluorescence signal 1 height (FL1H) vs fluorescence signal 2 area (FL2A) for the registration of all antigen-positive cells and approximately 20% of antigen-negative cells. Cell debris was excluded by setting the trigger level in FL2A. The total number of cells was documented after each live gate measurement. As a first step in the analysis of the acquired list mode data, the cell doublets were excluded by means of gating R1 in dot plot of PI fluorescence signal width (FL2W) vs FL2A ( Figure 1a ). Secondly these R1-gated cells were displayed in the dot plot FL1H vs FL2A as shown in Figure 1b . In this dot plot the antigen-positive cells were gated in R2. Combining R1 and R2 all plasma cells were included. These cells were depicted in the FL2A histogram (see Figure 1c ). The DNA index was determined by comparing the peak of aneuploid cells with the peak of diploid cells. As an internal standard for diploid DNA content, the T cells were immunophenotyped with anti-CD3 and prepared for additional DNA analysis. Apart from the percentage of aneuploid cells the diploid plasma cells were calculated.
Statistical differences were evaluated by Wilcoxon rank test. Correlation analysis as well as Wilcoxon rank tests were done using SPSS software.
Results
Detection of aneuploid myeloma cells in bone marrow by flow cytometry at diagnosis
Aneuploid cells were detected in 30 of 52 subsequently investigated myeloma patients. In most myelomas hyperdiploid cells with DNA indices at a range of 1.08 to 1.77 were present. Hypodiploid myeloma cells with DNA indices of 0.91 and 0.96 were detected in two patients and hypertetraploid cells (DNA: index 2.10) in one patient. The myeloma cell population of one patient had two aneuploid clones (DNA indices: 0.91 and 1.77). Looking at all patients, the percentage of diploid plasma cells was significantly lower than the percentage of aneuploid plasma cells (1.23% vs 7.93%; P = 0.0055). But in three patients the myeloma cell population consisted of aneuploid, as well as diploid, plasma cells. In these patients the percentages of diploid myeloma cells were 12.76%, 4.93% and 4.29%, respectively. Additional immunophenotyping for detection of aneuploid cells was neccessary in four patients, whereas in the other patients the one parameter analysis of DNA was sufficient at diagnosis. In these patients the percentage of aneuploid cells was lower (range: 0.26 to 0.79%) than in the others (range: 2.11% to 65.50%). 
Detection of aneuploid myeloma cells in PBSC harvests
In eight patients, 23 PBSC samples were investigated. With simultaneous measurement of DNA content and immunophenotyping with CD38 or B-B4 aneuploid cells were detectable in 13 of 23 PBSC harvests (range: 0.03% to 0.63%). Therefore in six out of eight patients aneuploid cells were detected in at least one PBSC harvest. Figure  2 shows the result of one measurement with detection of aneuploid myeloma cells in the B-B4 + cell population. Most of these B-B4-positive cells were diploid, but 0.02% aneuploid cells were detectable in the area (region) with the known DNA index of 1.17 (Figure 2b and c) . Even though the cells in the PBSC sample have low proliferative activity with a S-phase of 0.97%, the aneuploid cells are hidden in this S-phase, as shown in Figure 2a . When the DNA content was analyzed separately, aneuploid cells were detectable only in two PBSC samples from a patient with hypoploid myeloma (0.63% or 0.51%, respectively). The CD3-positive cells were analyzed as standard for diploid DNA content. If the DNA content of CD3-positive cells was measured, only one G0/G1 peak of these cells was detectable in all PBSC harvests. In all but two cases of PBSC samples the majority of B-B4-positive or CD38 ++ cells were diploid (Table 1) .
Detection of aneuploid myeloma cells in bone marrow by flow cytometry after chemotherapy
After at least three series of chemotherapy aneuploid cells were present in all bone marrow samples (range: 0.03-35.7%). In eight of 30 patients, the aneuploid cells could only be detected with additional immunophentyping (range: 0.03-1.10%). An example is shown in Figure 3 . In that case, the aneuploid cells with a DNA index of 1.15 (Figure 3a and b) decreased and the cells were only visible with additional immunophenotyping (Figure 3c and d) . After at least three cycles of chemotherapy, the percentage of aneuploid cells was decreased in 19 of 30 patients from 11.90% to 1.77%. In eight of 30 patients there was an increase of aneuploid cells from 2.65% to 8.75%. In the other three patients the percentage of aneuploid cells had not changed. The relation between diploid and aneuploid plasma cells did not change after therapy compared to the results at diagnosis.
Comparison of the percentage of aneuploid CD38
++ and B-B4
+ myeloma cells
This comparison was performed at diagnosis (n = 24), after therapy (n = 28) and in PBSC harvests (n = 13). The percentage of aneuploid myeloma cells stained with CD38 was in strong correlation to the measurement of B-B4-positive aneuploid cells as shown in Figure 4 (r = 0.9642; P Ͻ 0.001).
Discussion
With the method described here, residual aneuploid myeloma cells could be detected in 13 of 23 PBSC harvests, in all bone marrow samples after chemotherapy and in two out of three patients after autologous PBSC transplantation. The proposed method of additional immunophenotyping besides DNA quantification allows the detection of aneu- ploid cells at a higher sensitivity than one parameter DNA quantification. Analyzing the DNA content with the one parameter method the ratio of the normal diploid compared to the aneuploid cells would be mostly in favor of the diploid cells. However, the majority of diploid mononuclear cells will be excluded, if only the DNA content of immunophenotyped plasma cells is considered. Therefore the G0/G1 peak of malignant cells is recognisable in the DNA histogram of immunophenotyped cells (Figures 1-3) . Furthermore, in the one parameter analysis the hyperdiploid myeloma cells may be masked by the normal cells in Sphase. This problem is also circumvented with the gating of immunophenotyped plasma cells (Figure 3) . Finally, the coefficient of the variation (CV) of the G0/G1 peak influences the ability to detect aneuploid cells. In the one parameter analysis the CV in bone marrow and PBSC samples is increased because of the heterogeneous DNA staining index between hematopoietic subpopulations. 18 With additional immunophenotyping the DNA content of hematopoietic subpopulations can be considered. For example, the CV of the G0/G1 peak of the CD3-positive cells is significantly lower than the CV of all cells in the bone marrow samples. 19 This is also the case in the PBSC samples, but to a lesser degree (P = 0.036).
Oqueteau et al 20 
/CD38
++ cells can help to confirm the restriction of malignant plasma cells to the aneuploid population.
Other methods than those described here have been used for the assessment of residual myeloma cells. The most sensitive method is unequivocally the clone-specific PCR of the CDR III rearrangement. 4, 9, 10 This method is timeconsuming and expensive, because patient-specific oligonucleotide primers have to be generated. Furthermore, this method has only a limited ability to quantify the cell number. The analysis of single cells is possible with fluorescence microscopy and flow cytometry. In these methods the light chain restriction of myeloma cells is used as a marker for the detection and quantification of myeloma cells. 8 However, Pope et al 21 showed that the plasma cells in PBSC harvests from patients with multiple myeloma are predominantly polyclonal. The large number of polyclonal cells may mask the light chain restriction of the residual myeloma cell population. In our investigations the number of diploid plasma cells in PBSC samples is often more than 10-fold higher than that of the aneuploid myeloma cells. In most of these patients the malignant MM cells are only restricted to the aneuploid compartment, so that the results described here confirm the data of Pope et al. In summary, we propose the use of simultaneous immunophenotyping and DNA quantification as an additional method for the detection of mobilized myeloma cells in PBSC harvests and residual myeloma cells after chemotherapy in bone marrow. This relatively simple method can be used in about two-thirds of patients with multiple myeloma, corresponding to the incidence of aneuploidy in this disease. Whether this method has predictive importance for the duration of remission has to be investigated in further clinical studies.
